Media Center
In the media
Ability Pharma capta dos millones de dólares de la FDA para su ensayo clínico de páncreas
Planta Doce
22/10/2020
Ability Pharma receives the acknowledgement from Cerdanyola Empresarial
Parc UAB newsletter
22/11/2019
Ability reinforces the direction and rises 2 million euros from Inveready and Everis
Expansión
13/09/2019
A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer
RAC1
06/06/2019
The partner of AbilityPharma in China starts clinical trials with the licensed drug
Expansión
04/02/2019
AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA
Expansión
08/11/2018
TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech
Innovaspain
26/09/2018
LATEST NEWS
05.06.2025
Press Release
AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer + info
09.09.2024
Press Release
IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer + info
30.07.2024
Press Release
AbilityPharma receives WHO approval for its ABTL0812 anticancer drug to be named IBRILATAZAR + info
16.07.2024
Press Release
AGC Pharma Chemicals and AbilityPharma work together to produce innovative treatment for pancreatic cancer + info
11.03.2024
Press Release
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer + info
02.06.2023
Press Release
Ability Pharmaceuticals announces the presentation of the phase 2a results of ABTL0812 as first-line therapy in patients with lung cancer at the ASCO 2023 Annual Meeting in Chicago + info
14.12.2022
Press Release
AbilityPharma Achieves the 30% of the Estimated Recruitment for their Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as a First-Line Therapy Treatment in Advanced Pancreatic Cancer + info
21.11.2022
Press Release
AbilityPharma Obtains 1,5M € of Non-Dilutive Funding from Next Generation EU Funds to Further Study the Anticancer Immunomodulatory Effects of ABTL0812 + info
10.11.2022
Press Release
AbilityPharma will attend LSX investical showcase in London to meet with key investors and venture capital firms + info
